These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3128452)

  • 1. Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates.
    Berntorp E; Nilsson IM
    Eur J Haematol; 1988 Mar; 40(3):205-14. PubMed ID: 3128452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of the factor VIII protein and Factor XIII in various factor VIII concentrates.
    Nilsson IM; Holmberg L; Stenberg P; Henriksson P
    Scand J Haematol; 1980 Apr; 24(4):340-9. PubMed ID: 6774412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII:C and VIII:CAg response in patients with haemophilia A and von Willebrand's disease after administration of different factor VIII concentrates or plasma.
    Holmberg L; Borge L; Nilsson IM
    Br J Haematol; 1981 Apr; 47(4):587-96. PubMed ID: 6783063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand's disease.
    Berntorp E; Nilsson IM
    Vox Sang; 1989; 56(4):212-7. PubMed ID: 2503935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cryoprecipitate and Factor VIII commercial concentrates: in vitro characteristics and in vivo compartmental analysis.
    Morfini M; Longo G; Matucci M; Vannini S; Messori A; Filimberti E; Duminuco M; Avanzi G; Rossi-Ferrini P
    Ric Clin Lab; 1984; 14(4):681-91. PubMed ID: 6441235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Properties of factor VIII/von Willebrand factor in two highly-purified factor VIII concentrates, Hemofil M and Monoclate, using monoclonal antibodies].
    Tanaka I; Yoshioka A; Shima M; Fujiwara T; Terada S; Nakai H; Miyata S; Sawamoto Y; Kamisue S; Fukui H
    Rinsho Ketsueki; 1989 Jul; 30(7):951-7. PubMed ID: 2509762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates.
    Morfini M; Mannucci PM; Longo G; Cinotti S; Messori A
    Thromb Res; 1991 Feb; 61(3):285-90. PubMed ID: 1902997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in vivo study of a new factor VIII high purity preparation.
    Thorell L; Blombäck M; Blombäck B
    Thromb Res; 1983 Jul; 31(2):375-85. PubMed ID: 6415854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative study of concentrated blood derivatives of factor VIII].
    Baklaja R; Miletić V; Stajić M; Cvetković V; Grozdanić V
    Bilt Hematol Transfuz; 1984; 12(2):91-103. PubMed ID: 6441567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.
    Weiss HJ; Sussman II; Hoyer LW
    J Clin Invest; 1977 Aug; 60(2):390-404. PubMed ID: 17621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of the von Willebrand factor in virus inactivated F VIII concentrates: the impact of heat treatment.
    Ingerslev J; Bukh A; Wallevik K; Møller NP; Stenbjerg S
    Thromb Res; 1987 Jul; 47(2):175-82. PubMed ID: 3116714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Von Willebrand factor multimers in virus-inactivated plasmas and F VIII concentrates.
    Budde U; Drewke E
    Beitr Infusionsther Transfusionsmed; 1994; 32():408-14. PubMed ID: 9422121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low recovery in vivo of highly purified factor VIII in patients with hemophilia.
    Manno CS; Butler RB; Cohen AR
    J Pediatr; 1992 Nov; 121(5 Pt 1):814-8. PubMed ID: 1432437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of von Willebrand factor in factor VIII concentrates.
    Fricke WA; Yu MY
    Am J Hematol; 1989 May; 31(1):41-5. PubMed ID: 2495715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentrates.
    Kasper CK; Kim HC; Gomperts ED; Smith KJ; Salzman PM; Tipping D; Miller R; Montgomery RM
    Thromb Haemost; 1991 Dec; 66(6):730-3. PubMed ID: 1796419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentrates.
    Lawrie AS; Harrison P; Armstrong AL; Wilbourn BR; Dalton RG; Savidge GF
    Br J Haematol; 1989 Sep; 73(1):100-4. PubMed ID: 2508742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease.
    Tuddenham EG; Lane RS; Rotblat F; Johnson AJ; Snape TJ; Middleton S; Kernoff PB
    Br J Haematol; 1982 Oct; 52(2):259-67. PubMed ID: 6812613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.